Diabetes, COVID‐19, and questions unsolved

Recent evidence suggests a role for Diabetes Mellitus in adverse outcomes from COVID‐19 infection; yet the underlying mechanisms are not clear. Moreover, attention has turned to prophylactic vaccination to protect the population from COVID‐19‐related illness and mortality. We performed a comprehensi...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes/metabolism research and reviews 2023-07, Vol.39 (5), p.e3666-n/a
Main Authors: D’Souza, Felecia, Buzzetti, Raffaella, Pozzilli, Paolo
Format: Article
Language:English
Subjects:
ACE2
Angiotensin
Angiotensin-converting enzyme 2
CD147 antigen
Complications
COVID-19
COVID-19 - complications
COVID-19 - epidemiology
COVID-19 Vaccines
Diabetes
Diabetes mellitus
Diabetes Mellitus - epidemiology
Disease Progression
Furin
Humans
Hyperglycemia
Immunization
long COVID
Molecular modelling
Peptidyl-dipeptidase A
post‐COVID syndrome
Vaccine efficacy
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent evidence suggests a role for Diabetes Mellitus in adverse outcomes from COVID‐19 infection; yet the underlying mechanisms are not clear. Moreover, attention has turned to prophylactic vaccination to protect the population from COVID‐19‐related illness and mortality. We performed a comprehensive peer‐reviewed literature search on an array of key terms concerning diabetes and COVID‐19 seeking to address the following questions: 1. What role does diabetes play as an accelerator for adverse outcomes in COVID‐19?; 2. What mechanisms underlie the differences in outcomes seen in people with diabetes?; 3. Are vaccines against COVID‐19 efficacious in people with diabetes? The current literature demonstrates that diabetes is associated with an increased risk of adverse outcomes from COVID‐19 infection, and post‐COVID sequelae. Potential mechanisms include dysregulation of Angiotensin Converting Enzyme 2, Furin, CD147, and impaired immune cell responses. Hyperglycaemia is a key exacerbator of these mechanisms. Limited studies are available on COVID‐19 vaccination in people with diabetes; however, the current literature suggests that vaccination is protective against adverse outcomes for this population. In summary, people with diabetes are a high‐risk group that should be prioritised in vaccination efforts. Glycaemic optimisation is paramount to protecting this group from COVID‐19‐associated risk. Unsolved questions remain as to the molecular mechanisms underlying the adverse outcomes seen in people with diabetes; the functional impact of post‐COVID symptoms on people with diabetes, their persistence, and management; how long‐term vaccine efficacy is affected by diabetes, and the antibody levels that confer protection from adverse outcomes in COVID‐19.
ISSN:1520-7552
1520-7560
DOI:10.1002/dmrr.3666